25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AVXL (Anavex) Stock Analysis
Buy, Hold or Sell?

Let's analyze Anavex together

I guess you are interested in Anavex Life Sciences Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Anavex’s Financial Insights
  • 📈 Technical Analysis (TA) – Anavex’s Price Targets

I'm going to help you getting a better view of Anavex Life Sciences Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Anavex Life Sciences Corp

I send you an email if I find something interesting about Anavex Life Sciences Corp.

1. Quick Overview

1.1. Quick analysis of Anavex (30 sec.)










1.2. What can you expect buying and holding a share of Anavex? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.06
Expected worth in 1 year
$0.61
How sure are you?
42.5%

+ What do you gain per year?

Total Gains per Share
$-0.45
Return On Investment
-5.0%

For what price can you sell your share?

Current Price per Share
$9.09
Expected price per share
$7.18 - $14.25
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Anavex (5 min.)




Live pricePrice per Share (EOD)
$9.09
Intrinsic Value Per Share
$-5.65 - $-4.33
Total Value Per Share
$-4.59 - $-3.27

2.2. Growth of Anavex (5 min.)




Is Anavex growing?

Current yearPrevious yearGrowGrow %
How rich?$90.9m$135.6m-$30.1m-28.6%

How much money is Anavex making?

Current yearPrevious yearGrowGrow %
Making money-$12m-$10.3m-$1.6m-13.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Anavex (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#346 / 853

Most Revenue
#759 / 853

Most Profit
#545 / 853

Most Efficient
#229 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Anavex?

Welcome investor! Anavex's management wants to use your money to grow the business. In return you get a share of Anavex.

First you should know what it really means to hold a share of Anavex. And how you can make/lose money.

Speculation

The Price per Share of Anavex is $9.085. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Anavex.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Anavex, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.06. Based on the TTM, the Book Value Change Per Share is $-0.11 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Anavex.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.15-1.7%-0.14-1.5%-0.12-1.3%-0.14-1.5%-0.13-1.4%-0.09-1.0%
Usd Book Value Change Per Share-0.10-1.1%-0.11-1.2%-0.05-0.5%-0.06-0.6%0.040.4%0.020.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.10-1.1%-0.11-1.2%-0.05-0.5%-0.06-0.6%0.040.4%0.020.3%
Usd Price Per Share9.22-8.56-6.29-7.97-10.05-6.87-
Price to Earnings Ratio-14.95--15.24--13.71--14.68--20.23--21.33-
Price-to-Total Gains Ratio-89.99--76.50--362.66--121.62--109.86--150.82-
Price to Book Ratio8.71-7.12-3.97-5.52-7.66-14.38-
Price-to-Total Gains Ratio-89.99--76.50--362.66--121.62--109.86--150.82-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.085
Number of shares110
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.110.04
Usd Total Gains Per Share-0.110.04
Gains per Quarter (110 shares)-12.434.24
Gains per Year (110 shares)-49.7216.98
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-50-600177
20-99-11003424
30-149-16005141
40-199-21006858
50-249-26008575
60-298-310010292
70-348-3600119109
80-398-4100136126
90-447-4600153143
100-497-5100170160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%1.079.00.01.3%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%7.013.00.035.0%17.023.00.042.5%30.050.00.037.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.080.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%7.013.00.035.0%17.023.00.042.5%30.050.00.037.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Anavex Life Sciences Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.102-0.113+10%-0.049-52%-0.058-43%0.039-366%0.024-519%
Book Value Per Share--1.0591.228-14%1.579-33%1.488-29%1.421-25%0.819+29%
Current Ratio--13.4089.614+39%12.832+4%11.797+14%12.419+8%9.581+40%
Debt To Asset Ratio--0.1120.120-6%0.079+42%0.092+21%0.093+20%0.135-17%
Debt To Equity Ratio--0.1260.136-8%0.085+48%0.102+23%0.105+21%0.164-23%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--881630836.000837973959.000+5%672134236.500+31%809098805.333+9%980418893.450-10%657658498.350+34%
Eps---0.154-0.140-9%-0.121-22%-0.137-11%-0.127-17%-0.092-40%
Ev To Ebitda Ratio---16.485-14.997-9%-16.073-3%-16.079-2%-21.015+27%-20.473+24%
Free Cash Flow Per Share---0.145-0.108-26%-0.087-40%-0.090-38%-0.087-40%-0.063-57%
Free Cash Flow To Equity Per Share---0.170-0.109-36%-0.047-73%-0.050-70%0.043-497%0.028-715%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---4.329----------
Intrinsic Value_10Y_min---5.651----------
Intrinsic Value_1Y_max---0.278----------
Intrinsic Value_1Y_min---0.399----------
Intrinsic Value_3Y_max---0.954----------
Intrinsic Value_3Y_min---1.350----------
Intrinsic Value_5Y_max---1.773----------
Intrinsic Value_5Y_min---2.461----------
Market Cap780345173.000-1%791940836.000734821459.000+8%540486736.500+47%684788320.500+16%863404477.600-8%590412507.750+34%
Net Profit Margin----0%-0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%-0%
Pb Ratio8.579-1%8.7077.117+22%3.973+119%5.525+58%7.657+14%14.385-39%
Pe Ratio-14.731+1%-14.950-15.236+2%-13.708-8%-14.678-2%-20.234+35%-21.329+43%
Price Per Share9.085-1%9.2208.555+8%6.293+47%7.973+16%10.052-8%6.874+34%
Price To Free Cash Flow Ratio-15.652+1%-15.885-21.174+33%-19.559+23%-24.711+56%-32.526+105%-33.425+110%
Price To Total Gains Ratio-88.676+1%-89.993-76.498-15%-362.664+303%-121.624+35%-109.864+22%-150.818+68%
Quick Ratio--13.5179.602+41%12.746+6%11.745+15%12.370+9%9.518+42%
Return On Assets---0.129-0.102-21%-0.071-45%-0.086-34%-0.089-31%-0.164+27%
Return On Equity---0.146-0.116-20%-0.077-47%-0.095-35%-0.100-31%-0.202+38%
Total Gains Per Share---0.102-0.113+10%-0.049-52%-0.058-43%0.039-366%0.024-519%
Usd Book Value--90958000.000105473500.000-14%135600000.000-33%127819064.000-29%122022479.500-25%70340969.950+29%
Usd Book Value Change Per Share---0.102-0.113+10%-0.049-52%-0.058-43%0.039-366%0.024-519%
Usd Book Value Per Share--1.0591.228-14%1.579-33%1.488-29%1.421-25%0.819+29%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--881630836.000837973959.000+5%672134236.500+31%809098805.333+9%980418893.450-10%657658498.350+34%
Usd Eps---0.154-0.140-9%-0.121-22%-0.137-11%-0.127-17%-0.092-40%
Usd Free Cash Flow---12464000.000-9274500.000-26%-7500907.250-40%-7756779.667-38%-7495686.550-40%-5393573.525-57%
Usd Free Cash Flow Per Share---0.145-0.108-26%-0.087-40%-0.090-38%-0.087-40%-0.063-57%
Usd Free Cash Flow To Equity Per Share---0.170-0.109-36%-0.047-73%-0.050-70%0.043-497%0.028-715%
Usd Market Cap780345173.000-1%791940836.000734821459.000+8%540486736.500+47%684788320.500+16%863404477.600-8%590412507.750+34%
Usd Price Per Share9.085-1%9.2208.555+8%6.293+47%7.973+16%10.052-8%6.874+34%
Usd Profit---13243000.000-12042500.000-9%-10382000.000-22%-11778916.667-11%-10945350.000-17%-7913100.800-40%
Usd Revenue----0%-0%-0%-0%-0%
Usd Total Gains Per Share---0.102-0.113+10%-0.049-52%-0.058-43%0.039-366%0.024-519%
 EOD+3 -5MRQTTM+13 -19YOY+9 -233Y+9 -235Y+5 -2710Y+17 -15

3.3 Fundamental Score

Let's check the fundamental score of Anavex Life Sciences Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-14.731
Price to Book Ratio (EOD)Between0-18.579
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than113.517
Current Ratio (MRQ)Greater than113.408
Debt to Asset Ratio (MRQ)Less than10.112
Debt to Equity Ratio (MRQ)Less than10.126
Return on Equity (MRQ)Greater than0.15-0.146
Return on Assets (MRQ)Greater than0.05-0.129
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Anavex Life Sciences Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.621
Ma 20Greater thanMa 509.465
Ma 50Greater thanMa 10010.462
Ma 100Greater thanMa 2009.542
OpenGreater thanClose9.510
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Anavex Life Sciences Corp

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2025-08-23 11:16:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Anavex earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Anavex to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Anavex Life Sciences Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--73.5%+73.5%
TTM--154.3%+154.3%
YOY--207.9%+207.9%
3Y--272.9%+272.9%
5Y--345.5%+345.5%
10Y--504.5%+504.5%
4.3.1.2. Return on Assets

Shows how efficient Anavex is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Anavex to the Biotechnology industry mean.
  • -12.9% Return on Assets means that Anavex generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Anavex Life Sciences Corp:

  • The MRQ is -12.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.9%TTM-10.2%-2.7%
TTM-10.2%YOY-7.1%-3.1%
TTM-10.2%5Y-8.9%-1.3%
5Y-8.9%10Y-16.4%+7.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.9%-11.8%-1.1%
TTM-10.2%-11.6%+1.4%
YOY-7.1%-11.0%+3.9%
3Y-8.6%-11.9%+3.3%
5Y-8.9%-11.5%+2.6%
10Y-16.4%-13.6%-2.8%
4.3.1.3. Return on Equity

Shows how efficient Anavex is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Anavex to the Biotechnology industry mean.
  • -14.6% Return on Equity means Anavex generated $-0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Anavex Life Sciences Corp:

  • The MRQ is -14.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.6%TTM-11.6%-3.0%
TTM-11.6%YOY-7.7%-3.9%
TTM-11.6%5Y-10.0%-1.6%
5Y-10.0%10Y-20.2%+10.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.6%-13.7%-0.9%
TTM-11.6%-14.6%+3.0%
YOY-7.7%-15.0%+7.3%
3Y-9.5%-16.4%+6.9%
5Y-10.0%-16.9%+6.9%
10Y-20.2%-19.0%-1.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Anavex Life Sciences Corp.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Anavex is operating .

  • Measures how much profit Anavex makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Anavex to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Anavex Life Sciences Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--153.1%+153.1%
TTM--247.8%+247.8%
YOY--244.8%+244.8%
3Y--256.2%+256.2%
5Y--340.5%+340.5%
10Y--503.1%+503.1%
4.3.2.2. Operating Ratio

Measures how efficient Anavex is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Anavex Life Sciences Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.859-1.859
TTM-2.752-2.752
YOY-2.941-2.941
3Y-3.642-3.642
5Y-4.701-4.701
10Y-6.681-6.681
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Anavex Life Sciences Corp.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Anavex is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.41 means the company has $13.41 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Anavex Life Sciences Corp:

  • The MRQ is 13.408. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.614. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.408TTM9.614+3.794
TTM9.614YOY12.832-3.219
TTM9.6145Y12.419-2.806
5Y12.41910Y9.581+2.838
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.4083.457+9.951
TTM9.6143.689+5.925
YOY12.8324.093+8.739
3Y11.7974.571+7.226
5Y12.4195.722+6.697
10Y9.5816.137+3.444
4.4.3.2. Quick Ratio

Measures if Anavex is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Anavex to the Biotechnology industry mean.
  • A Quick Ratio of 13.52 means the company can pay off $13.52 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Anavex Life Sciences Corp:

  • The MRQ is 13.517. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.602. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ13.517TTM9.602+3.915
TTM9.602YOY12.746-3.144
TTM9.6025Y12.370-2.768
5Y12.37010Y9.518+2.852
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.5172.940+10.577
TTM9.6023.288+6.314
YOY12.7463.896+8.850
3Y11.7454.373+7.372
5Y12.3705.800+6.570
10Y9.5186.520+2.998
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Anavex Life Sciences Corp.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Anavex assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Anavex to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11 means that Anavex assets are financed with 11.2% credit (debt) and the remaining percentage (100% - 11.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Anavex Life Sciences Corp:

  • The MRQ is 0.112. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.120. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.112TTM0.120-0.008
TTM0.120YOY0.079+0.041
TTM0.1205Y0.093+0.027
5Y0.09310Y0.135-0.042
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1120.339-0.227
TTM0.1200.356-0.236
YOY0.0790.334-0.255
3Y0.0920.344-0.252
5Y0.0930.351-0.258
10Y0.1350.378-0.243
4.5.4.2. Debt to Equity Ratio

Measures if Anavex is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Anavex to the Biotechnology industry mean.
  • A Debt to Equity ratio of 12.6% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Anavex Life Sciences Corp:

  • The MRQ is 0.126. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.136. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.126TTM0.136-0.010
TTM0.136YOY0.085+0.051
TTM0.1365Y0.105+0.032
5Y0.10510Y0.164-0.059
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1260.393-0.267
TTM0.1360.439-0.303
YOY0.0850.435-0.350
3Y0.1020.462-0.360
5Y0.1050.463-0.358
10Y0.1640.511-0.347
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Anavex generates.

  • Above 15 is considered overpriced but always compare Anavex to the Biotechnology industry mean.
  • A PE ratio of -14.95 means the investor is paying $-14.95 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Anavex Life Sciences Corp:

  • The EOD is -14.731. Based on the earnings, the company is expensive. -2
  • The MRQ is -14.950. Based on the earnings, the company is expensive. -2
  • The TTM is -15.236. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-14.731MRQ-14.950+0.219
MRQ-14.950TTM-15.236+0.286
TTM-15.236YOY-13.708-1.528
TTM-15.2365Y-20.234+4.997
5Y-20.23410Y-21.329+1.096
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-14.731-2.447-12.284
MRQ-14.950-2.328-12.622
TTM-15.236-2.662-12.574
YOY-13.708-3.729-9.979
3Y-14.678-3.747-10.931
5Y-20.234-6.305-13.929
10Y-21.329-6.948-14.381
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Anavex Life Sciences Corp:

  • The EOD is -15.652. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -15.885. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -21.174. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.652MRQ-15.885+0.233
MRQ-15.885TTM-21.174+5.289
TTM-21.174YOY-19.559-1.615
TTM-21.1745Y-32.526+11.352
5Y-32.52610Y-33.425+0.899
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-15.652-3.310-12.342
MRQ-15.885-2.934-12.951
TTM-21.174-3.859-17.315
YOY-19.559-4.296-15.263
3Y-24.711-5.225-19.486
5Y-32.526-8.425-24.101
10Y-33.425-9.639-23.786
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Anavex is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 8.71 means the investor is paying $8.71 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Anavex Life Sciences Corp:

  • The EOD is 8.579. Based on the equity, the company is overpriced. -1
  • The MRQ is 8.707. Based on the equity, the company is overpriced. -1
  • The TTM is 7.117. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD8.579MRQ8.707-0.127
MRQ8.707TTM7.117+1.590
TTM7.117YOY3.973+3.144
TTM7.1175Y7.657-0.540
5Y7.65710Y14.385-6.727
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.5792.233+6.346
MRQ8.7072.000+6.707
TTM7.1172.205+4.912
YOY3.9732.413+1.560
3Y5.5252.571+2.954
5Y7.6573.756+3.901
10Y14.3854.451+9.934
4.6.2. Total Gains per Share

2.4. Latest News of Anavex Life Sciences Corp

Does Anavex Life Sciences Corp still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Anavex Life Sciences Corp to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-09-10
21:25
Notable Wednesday Option Activity: CLSK, BKD, AVXLRead
2025-08-19
19:38
High Growth US Tech Stocks To Watch In August 2025Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Anavex Life Sciences Corp.

4.8.1. Institutions holding Anavex Life Sciences Corp

Institutions are holding 38.323% of the shares of Anavex Life Sciences Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31BlackRock Inc7.84810.001267036231515742.3134
2025-06-30Vanguard Group Inc5.97880.000851068672046214.174
2025-03-31State Street Corp3.7630.0011321425680232733.265
2025-03-31Geode Capital Management, LLC2.30030.00131964810898884.7942
2025-03-31Nwam, LLC1.17110.73821000351873009.5613
2025-03-31Morgan Stanley - Brokerage Accounts1.01240.0005864728-39431-4.3611
2025-03-31Two Sigma Investments LLC1.00690.01588600988319710.7088
2025-03-31Susquehanna International Group, LLP0.92150.0012787100-347638-30.636
2025-03-31Northern Trust Corp0.86020.0009734731278303.9369
2025-06-30Charles Schwab Investment Management Inc0.83080.0011709616397055.9269
2025-03-31UBS Group AG0.71180.00160802018925645.194
2025-03-31Amvescap Plc.0.6490.0009554354-60694-9.8682
2025-03-31LPL Financial Corp0.640.0018546626452723482.1177
2025-03-31Two Sigma Advisers, LLC0.5950.0098508200176003.5874
2025-06-30Pier Capital, LLC0.49660.5966424148-31279-6.8681
2025-06-30Private Advisor Group, LLC0.46740.019839922518450085.9239
2025-03-31Millennium Management LLC0.39810.001634001913224163.6453
2025-06-30Goldman Sachs Group Inc0.34390.0004293780-117879-28.6351
2025-03-31Bank of America Corp0.31110.00022657246694433.6774
2025-06-30UBS Asset Mgmt Americas Inc0.26660.0004227741129107130.895
Total 30.57261.394626114017+2061892+7.9%

4.9.2. Funds holding Anavex Life Sciences Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Vanguard Total Stock Mkt Idx Inv3.03660.0013259379000
2025-07-31iShares Russell 2000 ETF2.31620.03691978421-37590-1.8646
2025-06-30Vanguard Institutional Extnd Mkt Idx Tr1.56190.0107133414253130.3998
2025-07-31SPDR® S&P Biotech ETF1.31420.26391122583335673.0823
2025-07-31Invesco Biotechnology & Genome ETF0.96734.138482627800
2025-05-31Fidelity Small Cap Index0.89160.0231761580-31-0.0041
2025-07-31iShares Russell 2000 Growth ETF0.86290.071373707500
2025-07-31iShares Biotechnology ETF0.5960.105850906943540.8627
2025-06-30Fidelity Extended Market Index0.5450.011465562-1215-0.2603
2025-06-30Vanguard Russell 2000 ETF0.49830.02984256394790412.6819
2025-07-31State St Russell Sm/Mid Cp® Indx SL Cl I0.49330.010942133300
2025-07-31Schwab US Small-Cap ETF™0.47180.0254403012-203-0.0503
2025-07-31State St Russell Sm Cap® Indx SL Cl I0.3540.037730239600
2025-06-30Vanguard Health Care ETF0.30860.0137263620-93-0.0353
2025-06-30Schwab Small Cap Index0.24640.02992104482277612.1361
2025-06-30NT R2000 Index Fund - NL0.23690.03022023382186512.1154
2025-07-31iShares Micro-Cap ETF0.22230.257118987500
2025-06-30Extended Equity Market Fund K0.2020.0109172540-3444-1.957
2025-06-30NT R2000 Index Fund - DC - NL - 30.18890.03021613211714711.8933
2025-06-30Fidelity Total Market Index0.1850.001315802600
Total 15.49925.139513239048+110350+0.8%

5.3. Insider Transactions

Insiders are holding 3.313% of the shares of Anavex Life Sciences Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-06-14Peter D.o. DonhauserBUY28353.64
2024-05-15Steffen ThomasBUY50004.52
2024-03-28Christopher U MisslingSELL733805.11
2023-06-28Christopher U MisslingSELL2680007.98
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-06-302024-09-302024-12-312025-03-312025-06-30
Other Current Assets  1,059-128931-220711-9702-1,522-820



5.2. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets102,432
Total Liabilities11,474
Total Stockholder Equity90,958
 As reported
Total Liabilities 11,474
Total Stockholder Equity+ 90,958
Total Assets = 102,432

Assets

Total Assets102,432
Total Current Assets101,164
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 101,164
Net Receivables 820
Other Current Assets -820
Total Current Assets  (as reported)101,164
Total Current Assets  (calculated)101,164
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,545
Long-term Liabilities3,929
Total Stockholder Equity90,958
Total Current Liabilities
Accounts payable 6,740
Total Current Liabilities  (as reported)7,545
Total Current Liabilities  (calculated)6,740
+/- 805
Long-term Liabilities
Long-term Liabilities  (as reported)3,929
Long-term Liabilities  (calculated)0
+/- 3,929
Total Stockholder Equity
Common Stock85
Retained Earnings -372,621
Other Stockholders Equity 463,494
Total Stockholder Equity (as reported)90,958
Total Stockholder Equity (calculated)90,958
+/-0
Other
Capital Stock85
Cash and Short Term Investments 101,164
Common Stock Shares Outstanding 85,381
Current Deferred Revenue805
Liabilities and Stockholders Equity 102,432
Net Debt -101,164
Net Invested Capital 90,958
Net Working Capital 90,958



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-31
> Total Assets 
0
0
0
1
0
0
20
12
5
15
0
0
131
93
112
7
1
79
799
409
73
229
1,572
330
489
65
1,279
203
85
191
22
13
80
0
3
393
151
10,293
9,314
7,354
7,050
6,364
8,043
15,470
14,024
12,115
9,844
9,499
21,374
23,607
24,907
27,838
28,344
25,896
26,795
24,376
22,096
20,550
21,968
25,329
31,424
31,021
31,630
34,542
54,334
83,574
166,420
161,616
156,896
160,276
160,221
152,705
148,372
159,186
157,810
154,386
148,070
144,750
141,535
135,567
124,043
117,139
102,432
102,432117,139124,043135,567141,535144,750148,070154,386157,810159,186148,372152,705160,221160,276156,896161,616166,42083,57454,33434,54231,63031,02131,42425,32921,96820,55022,09624,37626,79525,89628,34427,83824,90723,60721,3749,4999,84412,11514,02415,4708,0436,3647,0507,3549,31410,29315139330801322191852031,279654893301,57222973409799791711293131001551220001000
   > Total Current Assets 
0
0
0
1
0
0
20
12
5
15
0
0
59
14
11
6
1
79
743
407
71
228
1,537
326
486
62
1,276
201
83
190
21
13
80
0
3
393
149
9,222
8,199
7,351
7,049
6,363
8,041
15,469
14,023
12,114
9,843
9,446
21,322
23,554
24,854
27,786
28,291
25,812
26,742
24,324
22,096
20,550
21,817
25,329
31,424
31,021
31,630
34,542
54,334
83,574
166,420
161,616
156,896
160,276
160,221
152,705
148,372
159,186
157,810
154,386
148,070
144,516
141,535
135,567
124,043
117,139
101,164
101,164117,139124,043135,567141,535144,516148,070154,386157,810159,186148,372152,705160,221160,276156,896161,616166,42083,57454,33434,54231,63031,02131,42425,32921,81720,55022,09624,32426,74225,81228,29127,78624,85423,55421,3229,4469,84312,11414,02315,4698,0416,3637,0497,3518,1999,22214939330801321190832011,276624863261,537228714077437916111459001551220001000
       Cash And Cash Equivalents 
0
0
0
1
0
0
20
12
5
15
0
0
49
9
6
6
1
79
743
351
21
145
1,458
265
424
4
1,223
135
9
179
18
11
80
0
2
345
96
9,194
8,180
7,262
6,981
6,311
8,025
15,291
13,853
11,951
9,727
9,187
21,161
23,352
24,793
27,440
28,049
25,657
25,828
22,931
20,715
19,458
21,249
22,186
27,458
26,563
27,619
29,249
47,358
75,859
157,560
152,108
151,146
153,343
153,199
149,158
143,622
153,467
154,817
151,024
143,765
139,386
138,756
132,187
120,775
115,771
101,164
101,164115,771120,775132,187138,756139,386143,765151,024154,817153,467143,622149,158153,199153,343151,146152,108157,56075,85947,35829,24927,61926,56327,45822,18621,24919,45820,71522,93125,82825,65728,04927,44024,79323,35221,1619,1879,72711,95113,85315,2918,0256,3116,9817,2628,1809,194963452080111817991351,22344242651,4581452135174379166949001551220001000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
43
15
15
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000015154300000000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
38
38
9
21
1
3
1
0
0
0
0
0
0
0
0
0
77
0
0
0
77
92
79
48
79
49
61
8
10
7
5
6
1,870
30
76
93
2,643
3,731
4,152
3,548
4,849
6,578
7,328
8,601
9,137
5,372
6,469
6,560
3,193
4,094
4,738
2,165
2,709
3,549
3,785
1,720
2,449
2,557
666
820
8206662,5572,4491,7203,7853,5492,7092,1654,7384,0943,1936,5606,4695,3729,1378,6017,3286,5784,8493,5484,1523,7312,6439376301,8706571086149794879927700077000000000131219383800000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
10
5
5
0
0
0
0
56
50
83
79
23
62
49
32
65
70
10
3
1
0
0
2
48
53
28
19
89
68
52
16
101
77
85
68
180
111
142
53
336
235
151
909
1,252
1,350
1,016
475
501
235
306
463
444
399
387
258
372
378
465
462
354
656
982
828
653
756
1,345
1,059
931
711
702
-820
-8207027119311,0591,3457566538289826563544624653783722583873994444633062355014751,0161,3501,25290915123533653142111180688577101165268891928534820013107065324962237983505600005510000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
72
79
101
0
1
1
56
2
2
1
34
4
4
3
3
2
2
2
1
1
0
0
0
0
2
1,070
1,115
2
2
2
2
1
1
1
1
52
52
52
52
52
52
83
52
52
52
0
151
0
0
0
0
5,293
0
0
0
9,509
0
0
0
3,546,742
0
0
0
3,362
0
234
89
3,380
0
0
0
0003,3808923403,3620003,546,7420009,5090005,2930000151052525283525252525252111122221,1151,0702000011222334434122561101017972000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
2
2
1
1
4
4
3
3
2
2
2
1
1
0
0
0
0
2
2
2
2
2
2
2
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000011112222222000011222334411221111110000000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
72
78
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000000000001007872000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
72
78
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000000000001007872000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,069
1,113
0
0
0
0
0
0
0
0
53
52
53
53
52
53
83
52
52
1,381
1,092
151
0
3,966
4,458
0
-5,293
6,977
7,715
0
-9,509
5,750
6,934
7,022
-3,546,742
4,750
5,719,435
2,992,699
-3,362
4,305
0
-89
0
3,268
1,368
1,268
1,2681,3683,2680-8904,305-3,3622,992,6995,719,4354,750-3,546,7427,0226,9345,750-9,50907,7156,977-5,29304,4583,96601511,0921,381525283535253535253000000001,1131,0690000000000000000000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
151
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000001510000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
27
33
38
30
28
32
212
452
463
499
1,108
1,791
2,299
2,758
3,273
3,504
4,266
4,555
5,848
8,847
3,290
583
1,294
2,253
1,345
2,566
3,119
2,220
2,888
3,409
3,435
3,557
2,857
1,821
1,884
1,905
7,161
6,577
1,662
1,018
2,661
2,533
2,432
2,173
3,191
2,195
2,120
1,455
3,584
2,798
3,417
3,209
3,885
4,876
6,371
4,337
5,040
5,464
6,229
6,949
7,306
8,033
7,764
9,274
10,798
10,529
8,071
9,485
10,214
13,248
14,021
11,055
12,534
12,495
9,558
11,754
15,304
13,128
17,381
11,474
11,47417,38113,12815,30411,7549,55812,49512,53411,05514,02113,24810,2149,4858,07110,52910,7989,2747,7648,0337,3066,9496,2295,4645,0404,3376,3714,8763,8853,2093,4172,7983,5841,4552,1202,1953,1912,1732,4322,5332,6611,0181,6626,5777,1611,9051,8841,8212,8573,5573,4353,4092,8882,2203,1192,5661,3452,2531,2945833,2908,8475,8484,5554,2663,5043,2732,7582,2991,7911,108499463452212322830383327000
   > Total Current Liabilities 
0
0
0
27
33
38
30
28
32
212
452
463
499
1,108
1,791
2,299
2,758
3,273
3,504
4,098
4,431
4,692
7,883
3,290
583
1,294
2,253
1,345
2,566
3,119
2,220
2,888
3,409
3,435
3,557
1,953
1,821
1,883
1,904
1,441
1,418
1,528
1,001
2,661
2,532
2,432
2,173
3,191
2,195
2,120
1,455
3,584
2,798
3,417
3,209
3,885
4,876
6,371
4,337
5,040
5,464
6,229
6,949
7,306
8,033
7,764
9,274
10,798
10,529
8,071
9,485
10,214
13,248
14,021
11,055
12,534
12,495
9,558
11,754
15,304
13,128
17,381
7,545
7,54517,38113,12815,30411,7549,55812,49512,53411,05514,02113,24810,2149,4858,07110,52910,7989,2747,7648,0337,3066,9496,2295,4645,0404,3376,3714,8763,8853,2093,4172,7983,5841,4552,1202,1953,1912,1732,4322,5322,6611,0011,5281,4181,4411,9041,8831,8211,9533,5573,4353,4092,8882,2203,1192,5661,3452,2531,2945833,2907,8834,6924,4314,0983,5043,2732,7582,2991,7911,108499463452212322830383327000
       Short-term Debt 
0
0
0
0
0
0
20
20
20
85
273
0
200
675
1,296
1,550
1,550
2,005
2,524
2,507
2,428
2,425
2,602
2,492
200
200
828
868
1,156
1,201
49
299
599
761
758
211
200
194
201
192
98
90
93
85
82
88
88
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
88
0
0
0
0
0
0
0
0
0
0
0
0
917
-917
0
0
0
0
0000-917917000000000000880000000000000000088888285939098192201194200211758761599299491,2011,1568688282002002,4922,6022,4252,4282,5072,5242,0051,5501,5501,296675200027385202020000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
456
0
0
0
86
0
0
88
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000880086000456000000000000000000000000000000000000000
       Accounts payable 
0
0
0
17
24
10
10
8
12
127
179
0
299
433
495
0
749
1,268
0
1,592
0
0
0
798
383
1,094
1,367
410
1,397
0
0
2
3
3
2,766
1,711
1,592
1,666
1,671
1,221
1,284
1,398
1,208
2,471
2,370
2,308
2,027
3,061
2,127
2,002
1,394
3,584
2,798
3,417
3,209
2,955
4,876
6,371
4,337
3,523
3,127
3,650
3,980
3,989
4,217
3,658
4,177
4,740
4,635
2,632
3,127
3,825
5,288
6,282
4,153
4,322
4,292
3,726
3,503
9,627
4,567
6,997
6,740
6,7406,9974,5679,6273,5033,7264,2924,3224,1536,2825,2883,8253,1272,6324,6354,7404,1773,6584,2173,9893,9803,6503,1273,5234,3376,3714,8762,9553,2093,4172,7983,5841,3942,0022,1273,0612,0272,3082,3702,4711,2081,3981,2841,2211,6711,6661,5921,7112,766332001,3974101,3671,0943837980001,59201,2687490495433299017912712810102417000
       Other Current Liabilities 
0
0
0
10
9
27
0
0
0
0
0
0
0
675
0
0
2,758
2,005
3,504
0
4,431
4,692
7,883
798
200
1,294
1,425
68
13
3,119
2,220
2,587
3,406
3,433
33
30
29
23
32
28
36
40
51
105
80
36
58
14,837
68
118
60
3,584
2,798
3,417
3,209
929
4,876
6,371
4,337
1,516
2,336
2,579
2,969
3,317
3,817
3,619
4,653
5,615
5,450
4,995
5,914
6,389
7,960
6,823
6,902
7,295
7,286
4,915
7,334
4,835
7,732
9,555
0
09,5557,7324,8357,3344,9157,2867,2956,9026,8237,9606,3895,9144,9955,4505,6154,6533,6193,8173,3172,9692,5792,3361,5164,3376,3714,8769293,2093,4172,7983,584601186814,8375836801055140362832232930333,4333,4062,5872,2203,11913681,4251,2942007987,8834,6924,43103,5042,0052,75800675000000027910000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
168
124
1,155
963
0
0
0
0
0
0
0
0
0
0
0
0
904
904
1
1
5,720
5,159
134
17
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,516
2,336
2,579
0
3,317
3,817
3,619
0
5,615
5,079
3,076
5,914
4,269
7,043
6,822,838
5,985,658
7,295
7,286
4,915
7,334
4,835
7,732
9,555
3,929
3,9299,5557,7324,8357,3344,9157,2867,2955,985,6586,822,8387,0434,2695,9143,0765,0795,61503,6193,8173,31702,5792,3361,5160000000000000000171345,1595,720119049040000000000009631,1551241680000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000110000000000000000000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
151
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000001510000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
904
0
0
0
5,456
4,938
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000004,9385,45600090400000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
904
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31
0
0
0
0
151
0
0
0
0
0
0
0
0
444
0
0
0
444
0
0
0
0
0
0
0
0
0
0
0
00000000000444000444000000001510000310000000000000000090400000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-26
-33
-38
-10
-16
-28
-197
-452
0
-368
-1,015
-1,679
0
-2,757
-3,193
-2,705
-3,858
-4,483
-5,619
-7,275
-2,960
-94
-1,229
-973
-1,142
-2,481
-2,928
-2,198
-2,875
-3,329
-3,435
-3,553
-2,463
-1,670
8,408
7,409
193
473
4,702
7,024
12,809
11,491
9,683
7,671
6,308
19,179
21,487
23,452
24,254
25,545
22,479
23,586
20,492
17,220
14,179
17,632
20,290
25,960
24,792
24,681
27,237
46,301
75,810
157,146
150,818
146,368
152,205
150,737
142,491
135,124
145,165
146,755
141,852
135,575
135,192
129,781
120,263
110,915
99,758
90,958
90,95899,758110,915120,263129,781135,192135,575141,852146,755145,165135,124142,491150,737152,205146,368150,818157,14675,81046,30127,23724,68124,79225,96020,29017,63214,17917,22020,49223,58622,47925,54524,25423,45221,48719,1796,3087,6719,68311,49112,8097,0244,7024731937,4098,408-1,670-2,463-3,553-3,435-3,329-2,875-2,198-2,928-2,481-1,142-973-1,229-94-2,960-7,275-5,619-4,483-3,858-2,705-3,193-2,7570-1,679-1,015-3680-452-197-28-16-10-38-33-26000
   Common Stock
0
0
0
3
3
3
19
19
19
19
19
0
20
20
20
0
20
20
21
21
21
21
22
24
25
25
26
27
27
27
30
30
30
30
30
37
38
38
38
47
55
65
96
32
35
36
36
36
41
41
42
43
44
45
45
46
47
48
52
53
57
59
60
62
67
70
75
76
76
77
78
78
78
80
81
82
82
84
85
85
85
85
85
85858585858482828180787878777676757067626059575352484746454544434241413636363532966555473838383730303030302727272625252422212121212020020202001919191919333000
   Retained Earnings Total Equity00000000-282,923-271,643-258,536-245,564-231,273-218,906-208,468-197,586-185,868-175,688-167,532-159,677-153,712-147,225-139,989-133,397-131,348-124,273-116,265-108,932-103,139-100,290-95,538-91,479-86,324-82,714-81,165-78,018-71,507-69,267-67,236-63,281-59,325-55,085-53,360-52,573-42,874-41,865-40,846-41,205-38,216-38,065-37,9580000-29,203-27,78200000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
126
0
0
-1
-1
0
0
-2
-2
0
0
-3
-4
-4
-5
-5
-6
-6
-6
-6
0
0
-1
-1
-1
-1
-2
-2
-2
0
0
0
0
0
0
0
0
0
0
0
0
-293
0
0
0
0
0
0
0
251,498
0
0
0
-404
0
0
0
0
0
0
0
-234
-89
0
0
0
0
0000-89-2340000000-404000251,4980000000-293000000000000-2-2-2-1-1-1-100-6-6-6-6-5-5-4-4-300-2-200-1-1001260000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,783
28,034
0
0
0
0
34,600
34,600
34,600
38,645
39,078
49,595
49,605
52,079
53,138
59,082
65,031
74,061
76,128
78,914
79,142
84,290
100,303
104,159
109,734
115,689
121,039
122,724
126,679
129,378
133,438
138,404
148,928
153,634
165,892
171,958
178,333
186,852
213,766
251,428
342,938
348,328
354,760
371,438
381,932
387,977
393,582
416,728
429,596
0
0
0
0
0
0
0
0
00000000429,596416,728393,582387,977381,932371,438354,760348,328342,938251,428213,766186,852178,333171,958165,892153,634148,928138,404133,438129,378126,679122,724121,039115,689109,734104,159100,30384,29079,14278,91476,12874,06165,03159,08253,13852,07949,60549,59539,07838,64534,60034,60034,600000028,03426,78300000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
77
79
79
97
97
116
97
97
0
2,241
2,296
3,312
0
5,214
6,019
7,867
8,684
8,784
9,341
11,830
18,937
23,664
24,974
26,808
28,064
28,900
29,361
34,600
34,635
34,630
34,630
34,633
38,705
39,138
49,595
49,605
51,354
53,138
59,082
65,486
74,061
76,128
78,914
79,142
84,290
100,303
104,159
109,734
115,689
121,039
122,724
126,679
127,547
133,438
138,697
148,928
153,634
165,892
171,958
178,333
186,852
213,766
251,428
342,938
348,328
354,760
371,438
381,932
387,977
393,582
416,728
429,596
434,839
437,184
447,345
454,147
456,249
459,012
459,051
463,494
463,494459,051459,012456,249454,147447,345437,184434,839429,596416,728393,582387,977381,932371,438354,760348,328342,938251,428213,766186,852178,333171,958165,892153,634148,928138,697133,438127,547126,679122,724121,039115,689109,734104,159100,30384,29079,14278,91476,12874,06165,48659,08253,13851,35449,60549,59539,13838,70534,63334,63034,63034,63534,60029,36128,90028,06426,80824,97423,66418,93711,8309,3418,7848,6847,8676,0195,21403,3122,2962,241097971169797797977000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-09-30. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-52,877
Operating Income-52,877-52,877
 
Operating Expense (+$)
Research Development41,838
Selling General Administrative11,039
Selling And Marketing Expenses0
Operating Expense52,87752,877
 
Net Interest Income (+$)
Interest Income7,320
Interest Expense-0
Other Finance Cost-0
Net Interest Income7,320
 
Pretax Income (+$)
Operating Income-52,877
Net Interest Income7,320
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-43,002-62,752
EBIT - interestExpense = -95,879
-45,293
-43,002
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-95,879-43,002
Earnings Before Interest and Taxes (EBITDA)-45,293
 
After tax Income (+$)
Income Before Tax-43,002
Tax Provision-0
Net Income From Continuing Ops-43,002-43,002
Net Income-43,002
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses52,877
Total Other Income/Expenses Net9,875-7,320
 

Technical Analysis of Anavex
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Anavex. The general trend of Anavex is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Anavex's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Anavex Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Anavex Life Sciences Corp.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 11.70 < 13.99 < 14.25.

The bearish price targets are: 7.49 > 7.265 > 7.18.

Know someone who trades $AVXL? Share this with them.👇

Anavex Life Sciences Corp Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Anavex Life Sciences Corp. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Anavex Life Sciences Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Anavex Life Sciences Corp. The current macd is -0.27989189.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Anavex price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Anavex. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Anavex price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Anavex Life Sciences Corp Daily Moving Average Convergence/Divergence (MACD) ChartAnavex Life Sciences Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Anavex Life Sciences Corp. The current adx is 13.38.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Anavex shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Anavex Life Sciences Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Anavex Life Sciences Corp. The current sar is 10.34.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Anavex Life Sciences Corp Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Anavex Life Sciences Corp. The current rsi is 42.62. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Anavex Life Sciences Corp Daily Relative Strength Index (RSI) ChartAnavex Life Sciences Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Anavex Life Sciences Corp. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Anavex price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Anavex Life Sciences Corp Daily Stochastic Oscillator ChartAnavex Life Sciences Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Anavex Life Sciences Corp. The current cci is -171.38338879.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Anavex Life Sciences Corp Daily Commodity Channel Index (CCI) ChartAnavex Life Sciences Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Anavex Life Sciences Corp. The current cmo is -15.63290626.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Anavex Life Sciences Corp Daily Chande Momentum Oscillator (CMO) ChartAnavex Life Sciences Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Anavex Life Sciences Corp. The current willr is -83.2278481.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Anavex Life Sciences Corp Daily Williams %R ChartAnavex Life Sciences Corp Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Anavex Life Sciences Corp.

Anavex Life Sciences Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Anavex Life Sciences Corp. The current atr is 0.61035089.

Anavex Life Sciences Corp Daily Average True Range (ATR) ChartAnavex Life Sciences Corp Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Anavex Life Sciences Corp. The current obv is -19,178,767.

Anavex Life Sciences Corp Daily On-Balance Volume (OBV) ChartAnavex Life Sciences Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Anavex Life Sciences Corp. The current mfi is 59.35.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Anavex Life Sciences Corp Daily Money Flow Index (MFI) ChartAnavex Life Sciences Corp Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Anavex Life Sciences Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-07-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-20MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-21MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-09-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-11STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Anavex Life Sciences Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Anavex Life Sciences Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.621
Ma 20Greater thanMa 509.465
Ma 50Greater thanMa 10010.462
Ma 100Greater thanMa 2009.542
OpenGreater thanClose9.510
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Anavex with someone you think should read this too:
  • Are you bullish or bearish on Anavex? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Anavex? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Anavex Life Sciences Corp

I send you an email if I find something interesting about Anavex Life Sciences Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Anavex Life Sciences Corp.

Receive notifications about Anavex Life Sciences Corp in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.